Monopar Therapeutics price to book ratio MNPR

Market value divided by the book value of the company's net assets, since 2019.

Today, Oct 23, 2026: 3.6×
7-year median: 2.9×
Against its 7-year history: 59th; percentile: 0 is its lowest day, 100 its highest
7-year range: 0.7× to 54.2×
Peer median: 1.9×

Monopar Therapeutics' price to book ratio is 3.6× as of Oct 23, 2026.

That is above its 7-year median of 2.9×, close to the middle of its last 7 years.

Over that time it ranged from 0.7× in Nov 2023 to 54.2× in Dec 2019.

The median for 10 large drugmakers of a similar size is 1.9×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	3.6×	2.6×	6.0×
2025	3.2×	3.2×	51.7×
2024	26.2×	0.8×	27.5×
2023	0.8×	0.7×	3.8×
2022	2.4×	1.3×	2.9×
2021	1.9×	1.9×	6.7×
2020	4.0×	3.1×	44.2×
2019	39.8×	39.8×	54.2×

Against its peers

Companies in Drug Manufacturers - General nearest Monopar Therapeutics' size, closest first, today.

Company	Price to book ratio
MNPRMonopar Therapeutics	3.6×
ARVNArvinas	0.8×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	2.4×
ABUSArbutus Biopharma	3.2×
NATRNatures Sunshine Products	1.3×
AMPHAmphastar Pharmaceuticals	1.4×
OMEROmeros	n/m
Peer median	1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Monopar Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.